GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » Cyclically Adjusted PS Ratio

JW (Cayman) Therapeutics Co (HKSE:02126) Cyclically Adjusted PS Ratio : (As of Jun. 04, 2024)


View and export this data going back to 2020. Start your Free Trial

What is JW (Cayman) Therapeutics Co Cyclically Adjusted PS Ratio?

JW (Cayman) Therapeutics Co does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


JW (Cayman) Therapeutics Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Cyclically Adjusted PS Ratio Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial - - - - -

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of JW (Cayman) Therapeutics Co's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JW (Cayman) Therapeutics Co's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's Cyclically Adjusted PS Ratio falls into.



JW (Cayman) Therapeutics Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

JW (Cayman) Therapeutics Co does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.


JW (Cayman) Therapeutics Co  (HKSE:02126) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


JW (Cayman) Therapeutics Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


JW (Cayman) Therapeutics Co (HKSE:02126) Business Description

Traded in Other Exchanges
Address
No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Executives
Li Dan 2202 Interest of your spouse
Li Yiping James 2201 Interest of corporation controlled by you
Syracuse Biopharma (cayman) Ii, Ltd. 2501 Other
Bristol-myers Squibb Company 2201 Interest of corporation controlled by you
Celgene Corporation 2201 Interest of corporation controlled by you
Juno Therapeutics, Inc. 2101 Beneficial owner
Syracuse Biopharma (cayman) Ltd. 2501 Other

JW (Cayman) Therapeutics Co (HKSE:02126) Headlines

No Headlines